A study by Stanford University and the Institute for Bioengineering of Catalonia describes an innovative technology that enables the large-scale analysis of antibodies in biological samples. Using microscopic beads marked with stable isotopes, this advance surpasses traditional techniques, accelerating the study of immune responses and opening up new possibilities for biomedical research.
The Institute for Bioengineering of Catalonia (IBEC) is participating in the international SOLFEGE project, which aims to explore how different cell types coordinate with each other through soluble factors in the tumour microenvironment. This project has been made possible thanks to funding from the Human Frontier Science Program. SOLFEGE is a consortium led by the German Cancer Research Center (DKFZ), with IBEC and the Duke University, as partners.
The 1st Translational Collaboration Day between the Vall d’Hebron Institute of Research (VHIR) and the Institute of Bioengineering of Catalonia (IBEC), held on 21st November, was an opportunity to learn about the projects and research lines of both institutions and to promote interaction between professionals.
The latest developments in nanotechnology, biotechnology and medicine were presented at the NanoBio&Med 2024 International Conference, held this week at the Barcelona Science Park (PCB) from 5 to 7 November. This is an annual event designed to establish new collaborations and promote innovative projects in the scientific-industrial sector.
IBEC and the Blood and Tissue Bank of Catalonia (BST) held a day to explore new collaborations in bioengineering and translational medicine. The meeting, held yesterday at IBEC, highlighted innovative projects, presented a joint PhD programme and strengthened the link between biomedical research and clinical applications.
IBEC kicks off 2024 with the incorporation of three new research groups led by Manuel Salmerón Sánchez, Zaida Álvarez Pinto, and Xavier Rovira Clavé. With these additions, IBEC strengthens its position in the field of advanced and emerging therapies.
Xavier Rovira Clavé, currently a researcher at Stanford University’s School of Medicine, has been awarded the “Starting Grant” from the European Research Council (ERC) to carry out his project “SpaceClones” … Read more